Improving how RNA medicines are designed and delivered
Multidimensional approaches to understand and improve RNA therapeutic design and delivery
This project develops new tools and nanoparticle designs to help RNA medicines like mRNA vaccines work better and safer for people.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11323505 on NIH RePORTER |
What this research studies
Researchers will combine ultrasensitive detection methods, RNA engineering, and nanoparticle drug carriers to find practical design rules that make mRNA therapeutics function effectively in living systems. They will test how different RNA cargo features and carrier properties, alone and in combination, affect delivery and activity inside the body. The team will study how the host environment changes nanoparticles and how the therapies alter the host, while building high-throughput tools to measure these effects. The goal is to accelerate development of safer, more reliable RNA treatments that can be translated into clinical use for diseases such as COVID-19 and beyond.
Who could benefit from this research
Good fit: People with conditions that might be treated by RNA medicines (for example COVID-19, certain genetic diseases, or cancers) or healthy volunteers willing to provide samples for research could be relevant to follow or participate in future related opportunities.
Not a fit: Because this grant focuses on laboratory and preclinical development rather than providing therapies, patients seeking immediate treatment are unlikely to receive direct benefit from participation.
Why it matters
Potential benefit: If successful, this work could lead to more effective and safer RNA-based treatments and vaccines for a range of diseases.
How similar studies have performed: mRNA vaccines have proven highly effective, but many nanoparticle-based RNA therapies remain experimental, so this work builds on vaccine successes while addressing gaps that have limited broader clinical approvals.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Wu, Connie — University of Michigan at Ann Arbor
- Study coordinator: Wu, Connie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.